Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

← catalyst calendar

NCT05941442 · results posted

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
80actual
Sites
31
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Why the sponsor stopped it

Sponsor terminated due to significant enrollment and study design challenges

As filed on the registry record, in the sponsor's own words.

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-07-31actualWhen the study began enrolling
Primary completion2025-03-31actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-03-31actualThe whole study's end, after follow-up
First posted2023-07-12actualWhen this record first appeared on the registry
Results posted2026-05-07actualWhen the sponsor posted results to the registry
Record updated2026-05-07actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Panic Disorder

Interventions

  • Drug: Darigabat — also filed as CVL-865
  • Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF
Percentage of Participants Free of Panic Attacks as Assessed by Participant Daily eDiary During the Last Two Weeks of the Maintenance Treatment Period
measured Week 13-14

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-01-24 · 14.5 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-04-23 · 2.8 MB · SAP_001.pdf

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed